Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Skyrizi Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy CS2026D00116K

    Intravenous Skyrizi (risankizumab-rzaa) Coverage for Crohn's Disease and Ulcerative Colitis

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CS2026D00116K alerts

    Get alerted when Policy CS2026D00116K changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This medical benefit drug policy governs prior authorization and medical necessity for intravenous Skyrizi used for moderately to severely active Crohn's disease or ulcerative colitis. Self-administered subcutaneous Skyrizi is obtained under the pharmacy benefit.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyIntravenous Skyrizi coverage for Crohn's disease and ulcerative colitis
    Policy CodePolicy CS2026D00116K
    Change TypeAdministrative clarification
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for intravenous Skyrizi and limit initial authorization to three FDA-labeled induction doses.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added language stating that this Medical Benefit Drug Policy does not apply to Florida and directing readers to the state's Medicaid clinical policy.

    2Covered gastrointestinal indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Initial intravenous induction doses
    J2327Intravenous risankizumab-rzaa code
    GastroenterologistRequired specialist involvement
    Not allowedCombination therapy

    Coverage Criteria

    Initial therapy for Crohn's disease

    Covered when all of the following are met, including one qualifying prior-treatment pathway:

    Crohn's disease initial therapy

    • Disease activity

      • Diagnosis of moderately to severely active Crohn's disease.
    • ONE of the following prior-treatment pathways

      • History of failure to one conventional therapy at up to maximally indicated doses, unless contraindicated or associated with clinically significant adverse effects. Qualifying therapies include corticosteroids, 6-mercaptopurine, azathioprine, or methotrexate.
      • Prior treatment with a systemic targeted immunomodulator FDA-approved for the treatment of Crohn's disease.
    • Biologic DMARD history

      • History of failure, contraindication, or intolerance to two biologic DMARDs FDA-approved for the treatment of Crohn's disease.Two biologic DMARDs

        Document the drug, date, and duration of each trial.

    • Skyrizi is administered as three intravenous induction doses.Three intravenous induction doses

      Authorization will be issued for 3 induction doses.

    • Skyrizi induction dosing is in accordance with the FDA-labeled dosing for Crohn's disease.
    • The patient is not receiving Skyrizi in combination with another systemic targeted immunomodulator for treatment of the same indication.
    • Skyrizi is prescribed by or administered in consultation with a gastroenterologist.

    Initial therapy for ulcerative colitis

    Covered when all of the following are met, including one qualifying prior-treatment pathway:

    Ulcerative colitis initial therapy

    • Disease activity

      • Diagnosis of moderately to severely active ulcerative colitis.
    • ONE of the following prior-treatment pathways

      • Prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants, such as azathioprine or 6-mercaptopurine.
      • Prior treatment with a systemic targeted immunomodulator FDA-approved for the treatment of ulcerative colitis.
    • Skyrizi is administered as three intravenous induction doses.

    Skyrizi must not be administered in combination with another systemic targeted immunomodulator for treatment of the same indication.

    This policy applies to intravenous Skyrizi (risankizumab-rzaa). Self-administered subcutaneous Skyrizi is obtained under the pharmacy benefit and is not covered under this intravenous medical benefit policy.

    Coding and Clinical Parameters

    Procedure/Billing CodeHCPCS
    J2327Injection, risankizumab-rzaa, intravenous, 1 mg
    Crohn's Disease Diagnosis CodesICD-10
    K50.00Crohn's disease of small intestine without complications
    K50.011Crohn's disease of small intestine with rectal bleeding
    K50.012Crohn's disease of small intestine with intestinal obstruction
    K50.013Crohn's disease of small intestine with fistula
    K50.014Crohn's disease of small intestine with abscess
    K50.018Crohn's disease of small intestine with other complication
    K50.019Crohn's disease of small intestine with unspecified complications
    K50.10Crohn's disease of large intestine without complications
    K50.111Crohn's disease of large intestine with rectal bleeding
    K50.112Crohn's disease of large intestine with intestinal obstruction
    1–10 of 28
    1/3
    Ulcerative Colitis Diagnosis CodesICD-10
    K51.00Ulcerative (chronic) pancolitis without complications
    K51.011Ulcerative (chronic) pancolitis with rectal bleeding
    K51.012Ulcerative (chronic) pancolitis with intestinal obstruction
    K51.013Ulcerative (chronic) pancolitis with fistula
    K51.014Ulcerative (chronic) pancolitis with abscess
    K51.018Ulcerative (chronic) pancolitis with other complication
    K51.019Ulcerative (chronic) pancolitis with unspecified complications
    K51.20Ulcerative (chronic) proctitis without complications
    K51.211Ulcerative (chronic) proctitis with rectal bleeding
    K51.212Ulcerative (chronic) proctitis with intestinal obstruction
    1–10 of 50
    1/5
    Disease activity
    DiseaseCrohn's disease or ulcerative colitis
    Activity levelModerately to severely active
    Covered useTreatment with intravenous Skyrizi
    Intravenous induction course
    RouteIntravenous
    CourseInduction course
    Authorized quantity

    Provider Requirements and Coverage Risks

    Prior Authorization

    Intravenous Formulation Requires Review

    Prior authorization review applies to Skyrizi (risankizumab-rzaa) for intravenous use. Self-administered subcutaneous Skyrizi is obtained under the pharmacy benefit.

    Billing Rule

    Authorize Three Induction Doses

    Limit the initial authorization to three intravenous induction doses administered in accordance with the FDA-labeled regimen for the applicable indication.

    • Crohn's disease: three FDA-labeled intravenous induction doses.
    • Ulcerative colitis: three FDA-labeled intravenous induction doses.

    Clinical Background

    Skyrizi is a humanized IgG1 monoclonal antibody that selectively binds the p19 subunit of interleukin-23, inhibiting its interaction with the IL-23 receptor.

    Definitions

    Modified Mayo score
    DefinitionThree-component ulcerative colitis activity score
    Component 1Stool frequency, scored from 0 to 3
    Component 2Rectal bleeding, scored from 0 to 3
    Component 3Centrally read endoscopy subscore, scored from 0 to 3
    Clinical remission
    PopulationCited Crohn's disease studies
    CDAI definitionClinical remission was defined using Crohn's Disease Activity Index criteria

    Initial Therapy Criteria

    Crohn's disease

    Skyrizi is medically necessary for Crohn's disease when all of the following requirements are met:

    • Diagnosis of moderately to severely active Crohn's disease.
    • ONE qualifying prior-treatment pathway

      • History of failure to one conventional therapy at up to maximally indicated doses, unless contraindicated or associated with clinically significant adverse effects. Qualifying therapies include corticosteroids, 6-mercaptopurine, azathioprine, or methotrexate.
      • Prior treatment with a systemic targeted immunomodulator FDA-approved for the treatment of Crohn's disease.
    • History of failure, contraindication, or intolerance to two biologic DMARDs FDA-approved for the treatment of Crohn's disease.

    Step Therapy Requirements

    StepRequired prior therapyAlternative pathwayFailure or exception criteria
    1Use or failure of one conventional therapy at up to maximally indicated doses: corticosteroids, 6-mercaptopurine, azathioprine, or methotrexate.Prior treatment with an FDA-approved systemic targeted immunomodulator for Crohn's disease.Conventional therapy is not required when contraindicated or when clinically significant adverse effects are experienced. In addition, failure, contraindication, or intolerance to two FDA-approved biologic DMARDs for Crohn's disease is required.
    StepRequired prior therapyAlternative pathwayResponse criteria
    1Prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants, such as azathioprine or 6-mercaptopurine.Prior treatment with an FDA-approved systemic targeted immunomodulator for ulcerative colitis.Inadequate response to the therapeutic course is required for the corticosteroid and/or immunosuppressant pathway.

    Quantity Limits

    Skyrizi intravenous
    DrugSkyrizi intravenous
    Quantity limit3
    UnitInduction doses
    Applies perCourse
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyIntravenous Skyrizi coverage for Crohn's disease and ulcerative colitis
    Policy CodePolicy CS2026D00116K
    Change TypeAdministrative clarification
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for intravenous Skyrizi and limit initial authorization to three FDA-labeled induction doses.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersProvider Requirements and Coverage RisksClinical BackgroundDefinitionsInitial Therapy CriteriaStep Therapy RequirementsQuantity Limits
    Three intravenous induction doses

    Authorization will be issued for 3 induction doses.

  1. Skyrizi induction dosing is in accordance with the FDA-labeled dosing for ulcerative colitis.
  2. The patient is not receiving Skyrizi in combination with another systemic targeted immunomodulator for treatment of the same indication.
  3. Skyrizi is prescribed by or administered in consultation with a gastroenterologist.
  4. Three induction doses
    Dosing requirementMust follow FDA-labeled dosing for the applicable indication
    Documentation Required

    Gastroenterology Involvement Required

    Skyrizi must be prescribed by or administered in consultation with a gastroenterologist.

    Documentation Required

    Document Crohn's Disease Prior Therapy

    For Crohn's disease, document a history of failure of at least one conventional therapy at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects or other clinical circumstances make treatment inappropriate.

    • Acceptable conventional therapies include corticosteroids such as prednisone, methylprednisolone, or budesonide; 6-mercaptopurine; azathioprine; or methotrexate.
    Documentation Required

    Document Ulcerative Colitis Prior Therapy

    For ulcerative colitis, document a prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants, or applicable prior treatment with a systemic targeted immunomodulator FDA-approved for ulcerative colitis.

    • Examples of immunosuppressants include azathioprine and 6-mercaptopurine.
    • Applicable prior systemic targeted immunomodulators include agents such as adalimumab, Entyvio, Omvoh, Rinvoq, Simponi, Tremfya, Xeljanz/Xeljanz XR, ustekinumab, or Zeposia.
    Documentation Required

    Document Prior Crohn's Biologic Trials

    For Crohn's disease, document failure, contraindication, or intolerance to two biologic DMARDs FDA-approved for Crohn's disease and provide the treatment details for each trial.

    • Record the drug name, date, and duration of each biologic DMARD trial.
    • Examples include adalimumab, Cimzia, Entyvio, Omvoh, Rinvoq, Tremfya, and ustekinumab.
    Documentation Required

    Submit Disease and Treatment History

    Submit the diagnosis, disease activity, and applicable prior-treatment history supporting medical necessity for the requested indication.

    • Crohn's disease must be moderately to severely active.
    • Ulcerative colitis must be moderately to severely active.
    • Include conventional-therapy, immunosuppressant, and/or systemic targeted-immunomodulator treatment documentation as applicable.
    Denial Risk

    Crohn's Disease Criteria Not Met

    Coverage may be denied when Crohn's disease is not moderately to severely active or when the required conventional-therapy history is not documented, unless an applicable contraindication or clinically significant adverse effect is established.

    Denial Risk

    Insufficient Crohn's Biologic History

    Coverage may be denied when the patient has not failed, is not contraindicated to, or is not intolerant of two FDA-approved biologic DMARDs for Crohn's disease, or when the required trial details are missing.

    Denial Risk

    Ulcerative Colitis Criteria Not Met

    Coverage may be denied when ulcerative colitis is not moderately to severely active or when the required inadequate response or applicable prior-treatment history is not documented.

    Denial Risk

    Prohibited Combination Therapy

    Do not administer Skyrizi with another systemic targeted immunomodulator for treatment of the same indication.

    • Concurrent examples include adalimumab, Cimzia, Entyvio, Omvoh, Rinvoq, Simponi, Tremfya, Xeljanz/Xeljanz XR, ustekinumab, or Zeposia, as applicable to the indication.
    Denial Risk

    Regimen or Specialist Requirement Not Met

    Coverage may be denied when the requested regimen does not include three FDA-labeled intravenous induction doses or when prescribing or administration does not involve a gastroenterologist.

    Note

    FDA Approval Alone Does Not Establish Coverage

    FDA approval alone does not establish coverage. Coverage requires evaluation under the applicable benefit and federal, state, or contractual requirements.

    Patient-reported definitionClinical remission was also defined using patient-reported stool-frequency and abdominal-pain criteria
    Two biologic DMARDs

    Document the drug, date, and duration of each trial.

  5. Skyrizi is administered as three intravenous induction doses using FDA-labeled dosing for Crohn's disease.Three intravenous induction doses

    Authorization will be issued for 3 induction doses.

  6. Skyrizi is not administered in combination with another systemic targeted immunomodulator for treatment of the same indication.
  7. Skyrizi is prescribed by or administered in consultation with a gastroenterologist.
  8. Ulcerative colitis

    Skyrizi is medically necessary for ulcerative colitis when all of the following requirements are met:

    • Diagnosis of moderately to severely active ulcerative colitis.
    • ONE qualifying prior-treatment pathway

      • Prior or concurrent inadequate response to a therapeutic course of oral corticosteroids and/or immunosuppressants, such as azathioprine or 6-mercaptopurine.
      • Prior treatment with a systemic targeted immunomodulator FDA-approved for the treatment of ulcerative colitis.
    • Skyrizi is administered as three intravenous induction doses using FDA-labeled dosing for ulcerative colitis.Three intravenous induction doses

      Authorization will be issued for 3 induction doses.

    • Skyrizi is not administered in combination with another systemic targeted immunomodulator for treatment of the same indication.
    • Skyrizi is prescribed by or administered in consultation with a gastroenterologist.